Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) is scheduled to issue its quarterly earnings data on Monday, February 26th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
Shares of Rexahn Pharmaceuticals (NYSEAMERICAN RNN) opened at $1.78 on Monday. Rexahn Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $7.10. The stock has a market cap of $56.46, a PE ratio of -1.91 and a beta of -0.65.
RNN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Friday, November 10th. HC Wainwright reaffirmed a “buy” rating and issued a $19.50 target price on shares of Rexahn Pharmaceuticals in a research report on Monday, November 6th. Finally, ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $13.75.
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.